The combination of nutraceutical and simvastatin enhances the effect of simvastatin alone in normalising lipid profile without side effects in patients with ischemic heart disease

IJC Metabolic and Endocrine

Volumn 11, Issue , 2016, Pages 3-6

  Campolongo, Giuseppe ^a   Riccioni, Costanza Valentina ^b,c   Raparelli, Valeria ^b   Spoletini, Ilaria ^a   Marazzi, Giuseppe ^a   Vitale, Cristiana ^a   Volterrani, Maurizio ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Esserre Pharma Srl   (Italy)

Author keywords

Hyperlipidemia; Ischemic heart disease; Nutraceutical; Side effects; Simvastatin

Indexed keywords

ALANINE AMINOTRANSFERASE; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; BERGAMOT OIL; CREATINE KINASE; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NUTRACEUTICAL; PHYTOSTEROL; PLANT EXTRACT; SIMVASTATIN; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICHOKE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL SYNTHESIS; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRIORITY JOURNAL; THERAPY EFFECT;

EID: 84961196287     PISSN: 22147624     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcme.2016.03.001     Document Type: Article

References (36)

1. Ross R., Harker L. Hyperlipidemia and atherosclerosis. Science 1976, 193(4258):1094-1100.
2. Assmann G., Schulte H. The prospective cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am. Heart J. 1988, 116(6 Pt 2):1713-1724.
3. Lacoste L., Lam J.Y., Hung J., Letchacovski G., Solymoss C.B., Waters D. Hyperlipidemia and coronary disease. correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995, 92(11):3172-3177.
4. Levi F., Chatenoud L., Bertuccio P., Lucchini F., Negri E., La Vecchia C. Mortality from cardiovascular and cerebrovascular diseases in Europe and other areas of the world: an update. Eur. J. Cardiovasc. Prev. Rehabil. 2009, 16(3):333-350.
5. Mozaffarian D., Benjamin E.J., Go A.S., et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 2015, 131(4):e29-322.
6. Hubert H.B., Feinleib M., McNamara P.M., Castelli W.P. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham heart study. Circulation 1983, 67(5):968-977.
7. Odden M.C., Coxson P.G., Moran A., Lightwood J.M., Goldman L., Bibbins-Domingo K. The impact of the aging population on coronary heart disease in the United States. Am. J. Med. 2011, 124(9):827-833. (e5).
8. Williams R.R., Hunt S.C., Hopkins P.N., et al. Genetic basis of familial dyslipidemia and hypertension: 15-year results from Utah. Am. J. Hypertens. 1993, 6(11 Pt 2):319S-327S.
9. American Heart Association Nutrition C, Lichtenstein A.H., Appel L.J., et al. Diet and lifestyle recommendations revision 2006: A scientific statement from the American Heart Association Nutrition Committee. Circulation 2006, 114(1):82-96.
10. Catapano A.L., Reiner Z., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European society Of cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217(1):3-46.
11. Robinson J.G., Stone N.J. The 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk: a new paradigm supported by more evidence. Eur. Heart J. 2015, 36(31):2110-2118.
12. Slater E.E., MacDonald J.S. Mechanism of action and biological profile of HMG CoA reductase inhibitors. A new therapeutic alternative. Drugs 1988, 36(Suppl. 3):72-82.
13. Grundy S.M. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 1988, 319(1):24-33.
14. Brunton L., Chabner B., Knollmann B., Goodman, Gilman's The pharmacological basis of therapeutics 2010, 12th edition.
15. Libby P., Aikawa M. Mechanisms of plaque stabilization with statins. Am. J. Cardiol. 2003, 91(4 A):4B-8B.
16. Libby P., Ridker P.M. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am. J. Med. 2004, 116(Suppl. 6 A):9S-16S.
17. Glynn R.J., Danielson E., Fonseca F.A., et al. A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N. Engl. J. Med. 2009, 360(18):1851-1861.
18. Pyorala K., De Backer G., Graham I., Poole-Wilson P., Wood D. Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European society Of cardiology, European Atherosclerosis Society and European society Of hypertension. Atherosclerosis 1994, 110(2):121-161.
19. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur. Heart J. 1998, 19(10):1434-1503.
20. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc. Drugs Ther. 2005, 19(6):403-414.
21. Nordestgaard B.G., Chapman M.J., Humphries S.E., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur. Heart J. 2013, 34(45):3478-3490.
22. Fuhrman B., Aviram M. Flavonoids protect LDL from oxidation and attenuate atherosclerosis. Curr. Opin. Lipidol. 2001, 12(1):41-48.
23. Dugo P., Presti M.L., Ohman M., Fazio A., Dugo G., Mondello L. Determination of flavonoids in citrus juices by micro-HPLC-ESI/MS. J. Sep. Sci. 2005, 28(11):1149-1156.
24. Nogata Y., Sakamoto K., Shiratsuchi H., Ishii T., Yano M., Ohta H. Flavonoid composition of fruit tissues of citrus species. Biosci. Biotechnol. Biochem. 2006, 70(1):178-192.
25. Di Donna L., De Luca G., Mazzotti F., et al. Statin-like principles of bergamot fruit (Citrus bergamia): isolation of 3-hydroxymethylglutaryl flavonoid glycosides. J. Nat. Prod. 2009, 72(7):1352-1354.
26. Miceli N., Mondello M.R., Monforte M.T., et al. Hypolipidemic effects of Citrus bergamia risso et poiteau juice in rats fed a hypercholesterolemic diet. J. Agric. Food Chem. 2007, 55(26):10671-10677.
27. Mollace V., Sacco I., Janda E., et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. Fitoterapia 2011, 82(3):309-316.
28. Gliozzi M., Walker R., Muscoli S., et al. Bergamot polyphenolic fraction enhances rosuvastatin-induced effect on LDL-cholesterol, LOX-1 expression and protein kinase B phosphorylation in patients with hyperlipidemia. Int. J. Cardiol. 2013, 170(2):140-145.
29. Stroes E.S., Thompson P.D., Corsini A., et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, Aetiology and Management. Eur. Heart J. 2015, 36(17):1012-1022.
30. Gylling H., Plat J., Turley S., et al. Plant sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. Atherosclerosis 2014, 232(2):346-360.
31. Pittler M.H., Thompson C.O., Ernst E. Artichoke leaf extract for treating hypercholesterolaemia. Cochrane Database Syst. Rev. 2002, (3):CD003335.
32. Gebhardt R. Hepatocellular actions of artichoke extracts: stimulation of biliary secretion, inhibition of cholesterol biosynthesis and antioxidant properties. Phytomedicine 1996, (Suppl. 1):51.
33. Panizzi L., Scarpati M. Constitution of cynarine, the active principle of the artichoke. Nature 1954, 174:1062-1063.
34. Gebhardt R. Inhibition of hepatic cholesterol biosynthesis by artichoke leaf extracts is mainly due to luteolin. Cell Biol. Toxicol. 1997, 13:58.
35. Gardana C., Nalin F., Simonetti P. Evaluation of flavonoids and furanocoumarins from Citrus bergamia (bergamot) juice and identification of new compounds. Molecules 2008, 13(9):2220-2228.
36. Shin Y.W., Bok S.H., Jeong T.S., et al. Hypocholesterolemic effect of naringin associated with hepatic cholesterol regulating enzyme changes in rats. Int. J. Vitam. Nutr. Res. 1999, 69(5):341-347.